stoxline Quote Chart Rank Option Currency Glossary
Aeglea BioTherapeutics, Inc. (AGLE)
12.01  0.75 (6.66%)    11-27 16:00
Open: 10.87
High: 12.3399
Volume: 43,238
Pre. Close: 11.26
Low: 10.69
Market Cap: 49(M)
Technical analysis
2024-02-16 4:50:28 PM
Short term     
Mid term     
Targets 6-month :  33.47 1-year :  39.09
Resists First :  28.65 Second :  33.47
Pivot price 24.01
Supports First :  20.47 Second :  15.4
MAs MA(5) :  27.18 MA(20) :  23.35
MA(100) :  15.39 MA(250) :  11.48
MACD MACD :  2.3 Signal :  2
%K %D K(14,3) :  83 D(3) :  85.3
RSI RSI(14): 72.1
52-week High :  28.65 Low :  2.66
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AGLE ] has closed below upper band by 14.5%. Bollinger Bands are 60% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 28.03 - 28.13 28.13 - 28.22
Low: 26.47 - 26.59 26.59 - 26.7
Close: 27.3 - 27.51 27.51 - 27.67
Company Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Headline News

Mon, 27 Nov 2023
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD - PR Newswire

Thu, 09 Nov 2023
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - PR Newswire

Thu, 07 Sep 2023
Aeglea BioTherapeutics Announces Reverse Stock Split - PR Newswire

Tue, 05 Sep 2023
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones - PR Newswire

Tue, 05 Sep 2023
Aeglea BioTherapeutics Appoints Scott Burrows as CFO and Heidy Abreu King-Jones as CLO - citybiz

Fri, 11 Aug 2023
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 4 (M)
Held by Insiders 1.92e+006 (%)
Held by Institutions 0 (%)
Shares Short 114 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.884e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -9 %
Return on Assets (ttm) 485 %
Return on Equity (ttm) -41.9 %
Qtrly Rev. Growth 1.05e+006 %
Gross Profit (p.s.) 0
Sales Per Share -109.5
EBITDA (p.s.) -101946
Qtrly Earnings Growth -74.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -87 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.26
Price to Cash Flow -1.17
Stock Dividends
Dividend 0
Forward Dividend 139690
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android